AMD Alliance International
NEW YORK, April 14, 2011 /PRNewswire/ -- AMD is a leading cause of blindness in the developed world, affecting approximately 30 million people worldwide, with a price tag of nearly $343 billion. AMD is divided into two categories - dry and wet.
Upon being diagnosed, people with AMD must confront many doubts and hurdles:
As part of its global call to action, AMDAI will release a white paper on treating wet AMD as a chronic disease that focuses on the various elements of ongoing care that AMD patients require. The paper is the result of contributions by patient focus groups across Europe and the United States, and is informed by an expert panel of patient and policy advocates. Detailed findings of the white paper will be discussed via webcast on Monday, April 18 at 10am ET/3pm BT/4pm CET. To register for the webcast, please visit http://www.videonewswire.com/event.asp?id=78349.
The Webcast will be presented by experts in the field of AMD, who are also available for 1:1 interviews:
If you cannot attend the webcast but would like to schedule an interview, please contact Katie Compa at 415-362-1078 or [email protected].
About AMDAI
AMD Alliance International is the only international organization in the world dedicated exclusively to promoting awareness, treatment and research into macular degeneration, the leading cause of vision loss in the developed world. We are a membership organization comprised of the worlds' leading vision, seniors and research organizations from 25 countries. For more information please visit www.amdalliance.org.
Web site: http://www.amdalliance.org//